FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323048045> ?p ?o ?g. }

• W4323048045 endingPage "261" @default.
• W4323048045 startingPage "248" @default.
• W4323048045 abstract "Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and now tirzepatide, a dual GLP-1 RA/glucose-dependent insulinotropic polypeptide agonist, have numerous advantages in the treatment of type 2 diabetes and obesity, yet only 11% of patients with type 2 diabetes are prescribed a GLP-1 RA. This narrative review addresses the complexity and cost issues surrounding incretin mimetics to support clinicians.This narrative review summarizes key trials on the differing effects of incretin mimetics on glycosylated hemoglobin and weight, provides a table with rationale for how to interchange among agents, and summarizes the key factors that guide drug selection beyond guidance from the American Diabetes Association. To support proposed dose interchanges, we preferentially selected high-quality, prospective randomized controlled trials with direct comparisons of agents and doses when available.Tirzepatide produces the greatest reductions in glycosylated hemoglobin and weight, but its impact on cardiovascular events is still under investigation. Subcutaneous semaglutide and liraglutide are approved for weight loss specifically and are effective in the secondary prevention of cardiovascular disease. Although producing less weight loss, only dulaglutide has effectiveness in the primary and secondary prevention of cardiovascular disease. Semaglutide is the only orally available incretin mimetic; however, the oral formulation produces less weight loss versus its subcutaneous alternative and did not have cardioprotection in its outcomes trial. Although effective in controlling type 2 diabetes, exenatide extended release has the least impact on glycosylated hemoglobin and weight among commonly used agents, while not having cardioprotection. However, exenatide extended release may be preferred on some restrictive insurance formularies.Although trials have not explicitly studied how to interchange among agents, interchanges can be guided by comparisons between agents' impact on glycosylated hemoglobin and weight. Efficient changes among agents can help clinicians optimize patient-centered care, particularly in the face of changing patient needs and preferences, insurance formularies, and drug shortages." @default.
• W4323048045 created "2023-03-04" @default.
• W4323048045 creator A5017039674 @default.
• W4323048045 creator A5041479197 @default.
• W4323048045 creator A5044331487 @default.
• W4323048045 creator A5055796173 @default.
• W4323048045 creator A5087018300 @default.
• W4323048045 date "2023-03-01" @default.
• W4323048045 modified "2023-10-01" @default.
• W4323048045 title "Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review" @default.
• W4323048045 cites W1798757189 @default.
• W4323048045 cites W2049155190 @default.
• W4323048045 cites W2054981500 @default.
• W4323048045 cites W2104252114 @default.
• W4323048045 cites W2152984355 @default.
• W4323048045 cites W2425644022 @default.
• W4323048045 cites W2519510391 @default.
• W4323048045 cites W2590664415 @default.
• W4323048045 cites W2604469807 @default.
• W4323048045 cites W2754041380 @default.
• W4323048045 cites W2766836053 @default.
• W4323048045 cites W2774157762 @default.
• W4323048045 cites W2787255324 @default.
• W4323048045 cites W2948612418 @default.
• W4323048045 cites W2948622224 @default.
• W4323048045 cites W2973758715 @default.
• W4323048045 cites W3119307884 @default.
• W4323048045 cites W3127371223 @default.
• W4323048045 cites W3129305070 @default.
• W4323048045 cites W3133746780 @default.
• W4323048045 cites W3157081314 @default.
• W4323048045 cites W3175712753 @default.
• W4323048045 cites W3177122952 @default.
• W4323048045 cites W3184801395 @default.
• W4323048045 cites W3185437491 @default.
• W4323048045 cites W3197938525 @default.
• W4323048045 cites W4200521668 @default.
• W4323048045 cites W4206445899 @default.
• W4323048045 cites W4207005829 @default.
• W4323048045 cites W4210242902 @default.
• W4323048045 cites W4210417346 @default.
• W4323048045 cites W4281934192 @default.
• W4323048045 cites W4288740467 @default.
• W4323048045 cites W4296802076 @default.
• W4323048045 cites W4304080455 @default.
• W4323048045 cites W4307971805 @default.
• W4323048045 cites W4309160369 @default.
• W4323048045 cites W4311264067 @default.
• W4323048045 cites W4313529365 @default.
• W4323048045 cites W807162506 @default.
• W4323048045 doi "https://doi.org/10.1016/j.clinthera.2023.02.003" @default.
• W4323048045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36872170" @default.
• W4323048045 hasPublicationYear "2023" @default.
• W4323048045 type Work @default.
• W4323048045 citedByCount "0" @default.
• W4323048045 crossrefType "journal-article" @default.
• W4323048045 hasAuthorship W4323048045A5017039674 @default.
• W4323048045 hasAuthorship W4323048045A5041479197 @default.
• W4323048045 hasAuthorship W4323048045A5044331487 @default.
• W4323048045 hasAuthorship W4323048045A5055796173 @default.
• W4323048045 hasAuthorship W4323048045A5087018300 @default.
• W4323048045 hasConcept C126322002 @default.
• W4323048045 hasConcept C134018914 @default.
• W4323048045 hasConcept C2777180221 @default.
• W4323048045 hasConcept C2778881409 @default.
• W4323048045 hasConcept C2780533449 @default.
• W4323048045 hasConcept C2781308992 @default.
• W4323048045 hasConcept C2909862629 @default.
• W4323048045 hasConcept C511355011 @default.
• W4323048045 hasConcept C544821477 @default.
• W4323048045 hasConcept C555293320 @default.
• W4323048045 hasConcept C71924100 @default.
• W4323048045 hasConcept C98274493 @default.
• W4323048045 hasConceptScore W4323048045C126322002 @default.
• W4323048045 hasConceptScore W4323048045C134018914 @default.
• W4323048045 hasConceptScore W4323048045C2777180221 @default.
• W4323048045 hasConceptScore W4323048045C2778881409 @default.
• W4323048045 hasConceptScore W4323048045C2780533449 @default.
• W4323048045 hasConceptScore W4323048045C2781308992 @default.
• W4323048045 hasConceptScore W4323048045C2909862629 @default.
• W4323048045 hasConceptScore W4323048045C511355011 @default.
• W4323048045 hasConceptScore W4323048045C544821477 @default.
• W4323048045 hasConceptScore W4323048045C555293320 @default.
• W4323048045 hasConceptScore W4323048045C71924100 @default.
• W4323048045 hasConceptScore W4323048045C98274493 @default.
• W4323048045 hasIssue "3" @default.
• W4323048045 hasLocation W43230480451 @default.
• W4323048045 hasLocation W43230480452 @default.
• W4323048045 hasOpenAccess W4323048045 @default.
• W4323048045 hasPrimaryLocation W43230480451 @default.
• W4323048045 hasRelatedWork W1525424417 @default.
• W4323048045 hasRelatedWork W1943349542 @default.
• W4323048045 hasRelatedWork W2103969845 @default.
• W4323048045 hasRelatedWork W2604623769 @default.
• W4323048045 hasRelatedWork W2913046323 @default.
• W4323048045 hasRelatedWork W3025705096 @default.
• W4323048045 hasRelatedWork W3195538090 @default.
• W4323048045 hasRelatedWork W3213667413 @default.

• next